Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

Aspen Pharmacare Holdings Limited reported a significant financial performance for the first half of 2024, with the company surpassing its financial guidance amid strategic acquisitions and enhanced ...

At the 2025 Society for Neuroscience meeting, scientists discussed the adverse side effects of GLP-1 agonists and new ...

The implantation of electrodes in a patient with obesity has allowed the detection of the trace of tirzepatide in the nucleus ...

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals ...